Please login with your free MJA account to view this article in full
- Ken J Harvey1
- Agnes I Vitry2
- Elizabeth Roughead3
- Rosalie Aroni4
- Nicola Ballenden5
- Ralph Faggotter6
- 1 School of Public Health, La Trobe University, Bundoora, VIC.
- 2 School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA.
- 3 Monash Institute of Health Services Research, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC.
- 4 Australian Consumers’ Association, Marrickville, NSW.
- 5 Kings Park, SA.
Acknowledgements:
Heather Jones and Deborah Monk from Medicines Australia provided helpful information on regulatory matters. Contributors to the General Practice Computer Group Talk (GPCG_talk) email discussion forum provided vigorous and thoughtful opinions on the topic. In particular, we thank Dr Andrew Magennis, Medical Director, Health Communication Network (HCN) for responding to the debate and making a copy of HCN’s prescribing software (Medical Director) available for evaluation.
Competing interests:
K J H, A I V and R F are members of Healthy Skepticism (www.healthyskepticism.org), an organisation that aims to improve health by reducing harm from misleading drug promotion. K J H has had a long relationship with Therapeutic Guidelines Limited as author, Chairman of the Antibiotic Writing Committee and Board Member. He was also a member of a World Health Organization Expert Working Party that devised WHO Ethical Criteria for Medicinal Drug Promotion. A I V is a Consultant Editor at the Australian Medicines Handbook. E R is a Board Member of Therapeutic Guidelines Limited and a subscriber to Healthy Skepticism.
- 1. General Practice Computing Group. PIP (Practice Incentives Program). February 2004 update. Available at: http://www.gpcg.org/topics/pip.html (accessed May 2005).
- 2. Medicines Australia. Code of Conduct. Edition 14. Canberra: Medicines Australia Inc, 2003. Available at: http://www.medicinesaustralia.com.au/html/coc_full.asp (accessed May 2005)
- 3. Medicines Australia. Code of Conduct. Edition 14 Guidelines. Version 3. Canberra: Medicines Australia Inc, 2004. Available at: http://www.medicinesaustralia.com.au/html/coc_full.asp (accessed May 2005).
- 4. General Practice Computing Group. Listservs: GPCG_talk. Available at: http://www.gpcg.org/listservs/index.html (accessed May 2005).
- 5. De Schryver ELLM, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2002; (2): CD 001820.
- 6. Hussein Z, Wentworth JM, Nanverkis AJ, et al. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Aust 2004; 181: 536-539. <MJA full text>
- 7. Therapeutics Goods Administration. Potential safety risks with Celebrex. Media statement. 18 December 2004. Available at: http://www.tga.gov.au/media/2004/041220_celebrex.htm (accessed Jun 2005).
- 8. Burton B. Pfizer Australia is fined for misleading promotion of celecoxib. BMJ 2005; 330: 1230.
- 9. Therapeutic guidelines: antibiotic. Version 12. Melbourne: Therapeutic Guidelines Ltd, 2003.
- 10. Therapeutic guidelines: psychotropic. Version 5. Melbourne: Therapeutic Guidelines Ltd, 2003.
- 11. Prescribing benzodiazepines . . . ongoing dilemma for the GP. NPS News 2002; No. 24. Available at: http://www.nps.org.au/resources/NPS_News/news24/news24.pdf (accessed Jun 2005).
- 12. Therapeutic guidelines. Melbourne: Therapeutic Guidelines Ltd, 2005.
- 13. Australian medicines handbook. Adelaide: Australian Medicines Handbook Pty Ltd, 2005.
- 14. Adverse Drug Reactions Advisory Committee. Australian adverse drug reactions bulletin. Canberra: Therapeutic Goods Administration, 2005. Available at: http://www.tga.gov.au/adr/aadrb.htm (accessed May 2005).
- 15. Hassali A, Stewart K. Quality use of generic medicine. Aust Prescriber 2004; 27: 80-81.
- 16. Gould-Hurst P. Quality use of generic medicine [letter]. Aust Prescriber 2005; 28: 30-31.
- 17. Medicines Australia. Code of Conduct Committee outcomes July–December 2004. Canberra: Medicines Australia Inc, 2005. Available at: http://www.medicinesaustralia.com.au/html/coc_full.asp (accessed May 2005).
- 18. Medicines Australia. Code of Conduct. Annual report 2004. Canberra: Medicines Australia Inc, 2004. Available at: http://www.medicinesaustralia.com.au/html/coc_full.asp (accessed May 2005).
- 19. Medicines Australia. Code of Conduct. Annual report 2003. Canberra: Medicines Australia Inc, 2003. Available at: http://www.medicinesaustralia.com.au/html/coc_full.asp (accessed May 2005).
- 20. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behaviour of physicians. Am J Med 1982; 3: 4-8.
- 21. Dowden J. Coax, COX and cola. Med J Aust 2003; 179: 397-398. <MJA full text>
- 22. Australian Consumers’ Association. Prescribing software (and poll). Sydney: Australian Consumers’ Association, 2005. Available at: http://www.choice.com.au/viewArticle.aspx?id=104588&catId=100386&tid=100008&p=1 (accessed May 2005).
- 23. Profiting from pain: where prescription drug dollars go. Families USA Publication No. 02-105. Washington, DC: Families USA, 2002. Available at: http://www.familiesusa.org/site/DocServer/PPreport.pdf?docID=249 (accessed May 2005).
- 24. United Kingdom House of Commons Health Committee. The influence of the pharmaceutical industry. London: Stationery Office, 2005. Available at: http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed May 2005).
- 25. de Laat E, Windmeijer F, Douven R. How does pharmaceutical marketing influence doctors’ prescribing behaviour? The Hague: CPB Netherlands Bureau for Economic Policy Analysis, 2002. Available at: http://www.cpb.nl/nl/pub/bijzonder/38 (accessed May 2005).
Responses are now closed for this article.
Summary
Objective: To assess pharmaceutical advertisements in prescribing software, their adherence to code standards, and the opinions of general practitioners regarding the advertisements.
Design, setting and participants: Content analysis of advertisements displayed by Medical Director version 2.81 (Health Communication Network, Sydney, NSW) in early 2005; thematic analysis of a debate on this topic held on the General Practice Computer Group email forum (GPCG_talk) during December 2004.
Outcome measures: Placement, frequency and type of advertisements; their compliance with the Medicines Australia Code of Conduct, and the views of GPs.
Results: 24 clinical functions in Medical Director contained advertisements. These included 79 different advertisements for 41 prescription products marketed by 17 companies, including one generic manufacturer. 57 of 60 (95%) advertisements making a promotional claim appeared noncompliant with one or more requirements of the Code. 29 contributors, primarily GPs, posted 174 emails to GPCG_talk; there was little support for these advertisements, but some concern that the price of software would increase if they were removed.
Conclusions: We suggest that pharmaceutical promotion in prescribing software should be banned, and inclusion of independent therapeutic information be mandated.